December 24, 2024
3 min watch
Save
VIDEO: Trial examines hydroxyurea in patients with hemoglobin SC disease
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of hydroxyurea in patients with hemoglobin SC disease.
Mistry, an assistant professor at University of Pennsylvania, highlighted the phase 2 PIVOT study — a Ghanaian trial that treated patients with a medication generally used for sickle cell disease with hemoglobin SS phenotype.
“This is still not ready for the limelight yet. But I think that I was happy to see that we are improving options for patients that have limited options — for patients with hemoglobin SC disease with sickle-cell,” Mistry said.
Reference:
- Dei-Abdomakoh Y, et al. Abstract 3. Presented at: ASH Annual Meeting and Exposition; Dec. 7-10, 2024; San Diego.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mistry reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.